Secondary analyses evaluated ABASAGLAR® in patients previously treated with Lantus® insulin glargine
STOCKHOLM, Sept. 15, 2015 / PRNewswire — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR® (insulin glargine), Eli Lilly and Company and Boehringer …